Close-up of clinical monitor and ECG details tied to QT interval measurement

Definition & scope

Ibogaine is a psychoactive alkaloid found in Tabernanthe iboga and is being studied for addiction, PTSD, depression, and traumatic brain injury, but its key limiting toxicity is dose-dependent cardiac repolarization delay via hERG potassium-channel blockade, which lengthens the QT interval. The scope of “cardiac risk” here includes QTc prolongation, torsades de pointes, ventricular tachycardia/fibrillation, bradycardia, syncope, cardiac arrest, and death, plus risk amplification from electrolyte abnormalities, liver dysfunction, CYP2D6 variability, co-sedatives, and inadequate monitoring.

Cardiac risk is the central safety issue in any serious discussion of the drug: it reliably prolongs QTc, can trigger torsades de pointes and cardiac arrest, and has been linked to 30+ deaths in the medical literature and reports, mostly outside tightly monitored settings.

Interest spans from individuals exploring protocols like those discussed at ibogaine HCl information to people comparing overviews such as what is an ibogaine treatment, but the throughline is that the electrophysiology, not the psychology, anchors safety.

Why it matters in 2026

Texas committed $50 million to ibogaine clinical research in 2025, and the contract moved to UT Health Houston/UTMB in late 2025, making U.S.-based trials and safety infrastructure a live policy issue in 2026. A 2026 federal push to accelerate psychedelic review placed ibogaine in the national spotlight, even as major outlets emphasized its serious cardiac risks.

Clinical and review literature in 2025–2026 still describes ibogaine as promising but not yet supported by randomized controlled trials, with cardiac safety remaining the primary translational bottleneck. Public interest is increasing faster than formal approval pathways, which raises the risk of off-label hype, underground use, and clinic-shopping before standards are settled. For a focused discussion of these safety signals in lay terms, see this analysis of ibogaine side-effects and cardiac risks, which echoes concerns around QTc and monitoring.

Outside the U.S., clinics surface in searches ranging from ibogaine treatment options in Oklahoma to cross-border choices like ibogaine clinics in Mexico, underscoring the variability in protocols, telemetry, and emergency readiness that directly shapes risk.

Observed signals and monitored contexts

Clinical environment with continuous ECG, magnesium protocol notes, and crash cart readiness

Hospital-grade monitoring

In one observational study of 14 hospitalized patients, half reached dangerously abnormal rhythm measures after ibogaine. In a monitored cohort of 191 patients in St. Kitts, transient QT prolongation resolved and there were no clinically significant arrhythmias, hospitalizations, or deaths.

50%Abnormal rhythms in 14-patient inpatient series
191Monitored cases with no serious arrhythmias
24–72hTypical QT recovery window

Magnitude and time-course

QTc commonly rises into the 450–500 ms range during treatment and may go higher. QT prolongation can persist and then resolve over 24–72 hours after dosing, and many patients experience heart rates in the 50s or low 40s during treatment.

450–500QTc in milliseconds, commonly observed
40–50Bradycardic heart rates (bpm)
100%QTc prolongation reported by experts

Event rates and debate

In a Colorado expert interview, Andrew Monte said “100 percent” of people who get ibogaine experience QT prolongation and about 1 percent ultimately develop torsades de pointes. A 2024 open-label series cited in a 2025 review reported 30 patients who received ibogaine plus magnesium with no adverse cardiac events.

1%Estimated torsades risk in expert commentary
30Magnesium co-therapy cases without events
+QTcUniversal prolongation signal

For a technical clinical reference detailing toxicology and ECG findings, see the University of Virginia summary in PDF: ibogaine cardiac toxicology notes.

Hard statistics

  • 19 fatalities were identified in a 2012 review led by Alper among deaths following ibogaine ingestion from 1990–2008.
  • Subsequent updates cited in later coverage brought the total to 33 deaths linked to ibogaine in the literature.
  • In one observational study of 14 hospitalized patients, half reached dangerously abnormal rhythm measures after ibogaine.
  • In a monitored cohort of 191 patients in St. Kitts, transient QT prolongation resolved and there were no clinically significant arrhythmias, hospitalizations, or deaths.
  • In a Colorado expert interview, Andrew Monte said “100 percent” of people who get ibogaine experience QT prolongation and about 1 percent ultimately develop torsades de pointes.
  • A 2024 open-label series cited in a 2025 review reported 30 patients who received ibogaine plus magnesium with no adverse cardiac events.
  • QTc commonly rises into the 450–500 ms range during treatment and may go higher.
  • QT prolongation can persist and then resolve over 24–72 hours after dosing.
  • Many patients experience heart rates in the 50s or low 40s during treatment.
  • A recent Texas program award followed a $50 million state investment for FDA-approved trials.
  • A 2026 AP report said ibogaine is linked to more than 30 deaths in the medical literature.
  • A Partnership to End Addiction page says there have been more than 30 deaths in the last 40 years linked to ibogaine.
  • A NYT March 2026 profile reported vomiting occurs in about 75%–85% of users at least once in a session.
  • A Medscape summary notes no randomized, placebo-controlled trials of ibogaine exist.
  • A 2022 review cited by addiction education sources found only two scientifically sound trials of ibogaine for SUD.

As interest widens, people sometimes encounter disease-specific contexts like ibogaine treatment for Parkinson’s. Regardless of indication, the cardiac safety profile and telemetry standards remain the gating factor.

Process diary: translating risk into protocol

Cardiac risk is the central safety issue in any serious discussion of the drug: it reliably prolongs QTc, can trigger torsades de pointes and cardiac arrest, and has been linked to 30+ deaths in the medical literature and reports, mostly outside tightly monitored settings. Clinical and review literature in 2025–2026 still describes ibogaine as promising but not yet supported by randomized controlled trials, with cardiac safety remaining the primary translational bottleneck.

The scope of “cardiac risk” includes QTc prolongation, torsades de pointes, ventricular tachycardia/fibrillation, bradycardia, syncope, cardiac arrest, and death, plus risk amplification from electrolyte abnormalities, liver dysfunction, CYP2D6 variability, co-sedatives, and inadequate monitoring. Public interest is increasing faster than formal approval pathways, which raises the risk of off-label hype, underground use, and clinic-shopping before standards are settled.

Across headlines and policy hearings, the emphasis remains: dosing precision, baseline ECGs, electrolyte optimization, and multi-day telemetry shape outcomes more than enthusiasm or setting.

FAQ

What are the principal cardiac dangers?

QTc prolongation leading to torsades de pointes, ventricular tachycardia/fibrillation, bradycardia, syncope, and cardiac arrest are the core hazards, amplified by electrolyte abnormalities, hepatic dysfunction, CYP2D6 variability, sedative co-administration, and inadequate monitoring.

How often does QTc prolong?

Expert commentary describes QTc prolongation in essentially all recipients, with an estimated ~1% risk of torsades. QTc typically rises into the 450–500 ms range and may normalize over 24–72 hours post-dose.

Does clinical setting change outcomes?

Observational data show higher-risk rhythms in hospitalized patients without optimized protocols, whereas a monitored cohort of 191 patients reported transient QT changes without serious arrhythmias, hospitalizations, or deaths, highlighting the value of structured telemetry and electrolyte management.

Is there randomized evidence?

As of 2025–2026, there are no randomized, placebo-controlled trials; some series, including one with 30 patients receiving magnesium, reported no adverse cardiac events but remain non-randomized.

Where do people encounter ibogaine services?

Public interest has outpaced regulation, leading to clinic-shopping domestically and abroad, from state pages like Oklahoma treatment discussions to international providers detailed on Mexico clinic sites; the electrophysiology risks remain regardless of geography.

How do consumer resources frame the basics?

Introductory explainers vary in detail; some readers begin with concise definitions on ibogaine treatment overviews or formulation notes at HCl-focused resources, but all roads should lead back to the QTc-centered safety profile.

QTc prolongation • Torsades risk • Telemetry first • Magnesium protocols • Hepatic metabolism • CYP2D6 variability Arrhythmia surveillance • Policy funding • Monitored cohorts • 24–72h recovery • Bradycardia • Clinical thresholds QTc prolongation • Torsades risk • Telemetry first • Magnesium protocols • Hepatic metabolism • CYP2D6 variability Arrhythmia surveillance • Policy funding • Monitored cohorts • 24–72h recovery • Bradycardia • Clinical thresholds